has financial position that changed from its financial status as of December 31, 2019. The changes are described as follows: Assets Items that has significant changes Balance by Quarter Change Q1–20 Q4
changed from its financial status as of December 31, 2019. The changes are described as follows: Assets Items that has significant changes Balance by Quarter Change Q2–20 Q4–19 Q2–20 VS Q4–19 (MB) (MB
and other irregular items) reached Baht 585.7 million in Q3 2022; a 153.8% increase from that of Q3 2021 of Baht 230.8 million and 82.7% increase from average quarterly operating profit in 2021 of Baht
2023. Core operating profit (defined as Earnings before Interests and Taxes exclude interest income, gain (loss) on exchange rate and other irregular items) reached Baht 618.2 million in Q3 2023; a 5.6
its subsidiaries recorded revenue from sale of goods and rendering of services of THB 86,823 million (+29% YoY), with Net Profit of THB 3,344 million which was net profit attributable to owners of the
percent from Q3/2018). The Company recorded extraordinary items which affected the financial statements in the second half of the year, e.g., recognition of the costs of improvement of production efficiency
items included depreciation as well as accounting adjustment (ie provision of staff benefit and SW income) Page 2 of 4 was contributed by sub- specialty care particularly neurology, general surgery and
more orders from the products that passed main overseas customer’ testing from Q1-2 and also delivered a big lot of items, resulting in the increased revenue in second half of 2019. Overall, the Company
showing negative cash flow in amount of Baht 8.33 Million, consisted of operating loss of Baht 99.1 Million added back with major items of depreciation of Baht 56.7 Million, financing cost of Baht 6.7